Alterations of several genes have a role in leukemogenesis. These genes may have distinct functions or may be involved in the same complexes or pathways. Several recent studies have shown that the CBL gene, located in chromosome region 11q23.3, is mutated in chronic myeloid diseases. [1] [2] [3] CBL encodes an E3 ubiquitin ligase that attenuates the proliferative signal transduced by tyrosine kinase receptors such as FLT3 and KIT by enhancing their ubiquitination, downregulation, and lysosomal degradation. CBL mutations modify the protein activity 4 and lead to an increased and/or prolonged signal. The two other members of the CBL family, CBLB and CBLC, are also mutated in few cases of chronic myeloid diseases. 3 Mutations of CBL can be heterozygous or homozygous. Patients with homozygous mutations fare worse than patients with heterozygous ones. 3 Most often homozygosity results from acquired somatic uniparental disomy of chromosome arm 11q (11qUPD), which is detected by genome analyses using single-nucleotide polymorphism arrays. Malignant genomes can also be studied by array-comparative genomic hybridization (aCGH).
We used this latter technique to study 63 cases of myelodysplastic (MD) syndromes (MDSs) and 53 cases of chronic myelomonocytic leukemias (CMMLs). According to the WHO classification, 5 the MDS panel comprised 5 cases of refractory anemia (RA), 13 cases of RA with ring sideroblasts, 6 cases of refractory cytopenia with multilineage dysplasia (RCMD), 16 cases of RA with excess of blasts type 1 (RAEB1), 19 cases of RA with excess of blasts type 2 (RAEB2) and 4 cases of MDS-unclassified. The 53 CMML panel comprised 25 MD forms (leucocytosis count o13 Â 10 9 /l) and 28 myeloproliferative (MP) forms (leucocytosis count 413 Â 10 9 /l). 6 All patients signed an informed consent and the study was approved by our ethics committee. aCGH was done with high-density oligonucleotide microarrays (Hu-244A, Agilent Technologies, Massy, France), as described previously. 6 Two-thirds of the 63 MDS cases showed no copy number alterations (CNAs) (that is, neither gain nor loss) (Supplementary Table 1 Out of the 53 CMMLs, 37 cases (68%) showed no CNA (some of these cases have been reported previously 7 ) (Supplementary Table 2 ). Ten cases had a single or few small CNAs, including loss of NF1, RB1 or TET2. One of these, HD-0176, showed a gain of SH3KBP1. Patient HD-0176 was a 46-year-old man diagnosed with CMML1 in December 2006.
Therapeutic abstention was decided. Ten months later, the patient died of meningitis. The HD-0176 genome did not have any other alteration except a gain of the AHR gene at 7p21, the role of which is unknown; it is noticeable, however, that AHR can act as CBL, as an E3 ubiquitin ligase, 8 and that both AHR and CBL participate in the JUN and P38 kinase pathways.
In the same panel we searched for mutations in exons 8 and 9 of CBL. DNA sequencing was done as described. 7 Five MDS cases, all RAEB2, were mutated in CBL (7.8%): p.Glu366Lys, p.Tyr368X, p.Leu380Pro, p.Lys381Arg and p.Pro417Leu (Supplementary Table 1 ). One substitution occurred in the case with trisomy 11 (HD-0264). Mutations of CBL, including two homozygous, were found in five CMML cases (B10%, four in MP forms: p.Tyr317His, p.Cys396Tyr, p.Cys404Tyr and p.Phe418Ser; one in MD form: p.Cys404Tyr) (Supplementary Table 2 ). The results are summarized in Table 1 .
SH3KBP1 (SH3-domain kinase binding protein 1), also called CIN85 (CBL-interacting protein of 85 kDa), codes for a cytoplasmic adaptor molecule that interacts and cooperates with CBL to regulate signaling.
9-11 RCMD HD-0747 and MP-CMML HD-0176, the two cases with Xp22 SH3KBP1 gain, occurred in males and displayed a normal karyotype. They were not mutated in CBL exons 8 and 9. They were not mutated either in ASXL1, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes (not shown). As determined by aCGH, the SH3KBP1 gain was limited to an additional copy. This duplication and the CBL UPD11q suggest that limited variations of the pathway are sufficient to induce an effect on signaling. Mutations of CBL have an effect on cell proliferation.
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SH3KBP1/CIN85 cooperates with CBL in the downregulation of signaling receptors. 10 Because of UPD11q two copies of the mutated CBL gene are often present in the malignant clone. In a similar way, it could be possible that the SH3KBP1 duplicated gene is mutated. We have looked in our Affymetrix microarray data for the expression of SH3KBP1 in HD-0176, for which we had mRNA. The level of expression was not overtly modified as compared with normal bone marrow or other MDS/CMML samples.
In summary, we have found two examples of alteration of a gene encoding a CBL interactor. This alteration may play a role similar to that of CBL mutations in chronic myeloid diseases. Although the anomaly is rare (1.7% in our series), it is not insignificant. First, the number of CNAs was globally low; in comparison we found only two deletions of TET2 and one deletion of ASXL1 in the same panel. Second, SH3KBP1 gain increases by about 20% the cases with alteration of the CBL pathway (2 cases out of 116 tested; to be compared with 10 mutated CBL). Third, it shows specificity, as we have not detected such gain in 300 breast or colon cancers (not shown). This emphasizes the importance of CBL-associated deregulation of signaling in chronic myeloid diseases and constitutes an incentive to look for alterations in other members of the CBL/CIN85 pathway. 12 In that respect we found a gain of the gene encoding MAP3K4, an interactor of CIN85, 13 in a RAEB1 with complex aCGH profile, and a gain of the gene encoding the CBL interactor ARHGEF7/bPIX in an RCMD in a reported study.
14 Whether other E3 ubiquitin ligases (for example, AHR or SCF components) may have a role in these diseases also needs to be investigated. Letters to the Editor
